Guardant Health is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. GuardantOMNI differs from Guardant360 in that biopharma companies use it for comprehensive genomic profiling in both immuno-oncology and targeted therapy areas. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. This table compares Guardant Health and CareDx's net margins, return on equity and return on assets. CareDx beats Guardant Health on 8 of the 15 factors compared between the two stocks. Data Sources: Yahoo Finance, Illumina, Guardant Health. Looking for new stock ideas? See what's happening in the market right now with MarketBeat's real-time news feed. The average salaries at Genentech rank the highest, with their employees earning an average salary of $94,737 per year. 76.2% of Guardant Health shares are held by institutional investors. Guardant Health's main competitors include Tempus, 2cureX, Spago Nanomedical and Advaite. Guardant Health has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Guardant Health is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks. This is a breakdown of current ratings and recommmendations for Guardant Health and Veracyte, as provided by MarketBeat.com. Companies like Guardant Health. Clinicians use it to inform the selection of cancer therapy for their patients, whereas biopharmaceutical companies use it to accelerate drug development and commercialize products. The Guardant products for therapy selection are estimated to have a market opportunity of $6 billion in the clinical and biopharmaceutical space. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Both companies have plenty of cash to operate, but Illumina commands a market valuation of $54.2 billion, nearly seven times the $7.9 billion market cap of Guardant Health. Advanced Jackpot: Drills are Running Hot like Lava for this Company´s South American Super Project, These unique rock formations now host some of the highest-grade gold mineralization on the planet. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 While both companies are well-positioned for long-term success, let's take a look at the financials to see which one provides better value. Companies in the industry of "medical laboratories" are considered alternatives and competitors to Guardant Health, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), Invitae (NVTA), Natera (NTRA), CareDx (CDNA), and Veracyte (VCYT). December 8, 2020. Comparatively, 2.9% of Invitae shares are held by company insiders. The traditional methods of detection occur after the cancer is suspected and involves the use of invasive procedures such as surgery to extract a sample, while liquid biopsies are simple blood tests that have the potential to detect cancer at earlier stages. Benefits information above is provided anonymously by current and former Guardant Health employees, and may include a summary provided by the employer. Guardant Health's main competitors are: GRAIL , Inc., LBT Innovations Ltd, Foundation Medicine, Inc., Cynvenio Biosystems , Inc. What companies has Guardant Health acquired? This table compares Guardant Health and Laboratory Co. of America's gross revenue, earnings per share (EPS) and valuation. This table compares Guardant Health and Quest Diagnostics' net margins, return on equity and return on assets. 9.9% of Guardant Health shares are owned by insiders. Guardant Health competes with Agilent, Global Cord, Laboratory, and Dermtech. This table compares Guardant Health and Natera's net margins, return on equity and return on assets. See you at the top! This is a summary of recent ratings and price targets for Guardant Health and Laboratory Co. of America, as reported by MarketBeat. Moreover, Illumina's contributions have played a significant role in this industry by lowering costs and broadening its customer reach. What Should Investors Make of Guardant Health's Newest Competitor? Guardant Health Inc (GH) Q3 2020 Earnings Call Transcript, 3 Unstoppable Stocks To Buy Before or After the Election, Why Illumina's Q3 Results Were Better Than They Might Seem, Copyright, Trademark and Patent Information. Comparatively, 78.9% of Quest Diagnostics shares are held by institutional investors. Learn about financial terms, types of investments, trading strategies and more. This table compares Guardant Health and Laboratory Co. of America's net margins, return on equity and return on assets. Returns as of 12/15/2020. Guardant Health (NASDAQ:GH) and Invitae (NYSE:NVTA) are both large-cap medical companies, but which is the superior investment? Global Liquid Biopsy Products Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 is a well presented and highly researched market synopsis that demonstrates a thoroughly unbiased portrayal of the current market conditions to assist enthusiastic investors and established players to manage high potential growth and steady revenue output through the entire growth span. Liquid biopsies have the potential to improve clinical outcomes, lower healthcare costs, and enable biopharma companies to advance new therapies. This table compares Guardant Health and Veracyte's net margins, return on equity and return on assets. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Together they have raised over 2.9B between their estimated 271.6K employees. Guardant Health has acquired the companies: Bellwether Bio, Inc. Comparatively, 82.3% of Laboratory Co. of America shares are owned by institutional investors. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Let's conquer your financial goals together...faster. • List of GH Customers for the same period Guardant Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 % . Comparatively, 84.1% of Natera shares are held by institutional investors. Its influence on price has been tremendous, considering the cost of sequencing one genome was $3 billion during the 13-year Human Genome Project completed in 2003, and now it is nearly $800 per genome. Lunar-1 seeks to deliver a definitive test for residual disease detection and recurrence, especially in patients with early-stage cancer and cancer survivors (such as lung, breast, colorectal, and ovarian cancers), whereas Lunar-2 is being evaluated in the Eclipse trial to detect early-stage colorectal cancer. Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. Get daily stock ideas top-performing Wall Street analysts. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. for the same period Guardant Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 %. Veracyte has lower revenue, but higher earnings than Guardant Health. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. View our full suite of financial calendars and market data tables, all for free. Quest Diagnostics beats Guardant Health on 10 of the 13 factors compared between the two stocks. Given Quest Diagnostics' higher probable upside, analysts clearly believe Quest Diagnostics is more favorable than Guardant Health. Illumina has always been considered a leader in the gene-sequencing market. Guardant Health filed suit against Foundation Medicine in a U.S. District Court in California for false advertising and unfair competition. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Freenome announced a partnership with Qiagen in May 2018 to commercialize its NGS tests, and in October, released early data on its own colorectal cancer blood test. 9.9% of Guardant Health shares are held by company insiders. Maxx Chatsko Comparatively, Laboratory Co. of America has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Guardant Health, Inc. Common Stock (GH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Follow a manual added link. This table compares Guardant Health and CareDx's gross revenue, earnings per share and valuation. In some cases apparently high growth rates may be caused by data that weren't available in previous years. Learn about Guardant Health , including insurance benefits, retirement benefits, and vacation policy. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. CareDx has lower revenue, but higher earnings than Guardant Health. Learn more. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. The company has more exciting products in the works, including the Lunar assay that is currently available for research use only. Comparatively, CareDx has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Now FDA Approved. We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. Guardant Health is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Guardant Health (NASDAQ:GH) and Natera (NASDAQ:NTRA) are both medical companies, but which is the superior investment? 76.2% of Guardant Health shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Where is Guardant Health headquarters? Impact of Covid 19 on the Tumor Testing market in 2020 in depth research on prices , stocks , volume and growth , latest news and results , expansion plan , current business strategy , key company , sales , revenue and competition , production and consumption , supply and demand , industry and business studies , impact of Covid 19 buyers and sellers and forecast for 2020 – 2025 Invitae has a consensus price target of $38.6071, suggesting a potential downside of 23.84%. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Invitae. The companies' financial situations are similar, but Illumina has a larger growth opportunity once the COVID-19 impact settles. Should You Buy the Peloton (NASDAQ: PTON) Rally? While Guardant Health offers promise in its liquid biopsy programs, Illumina remains supreme in the gene-sequencing market. Learn everything you need to know about successful options trading with this three-part video course. Stock Advisor launched in February of 2002. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. 76.2% of Guardant Health shares are held by institutional investors. CareDx has a consensus price target of $58.00, suggesting a potential downside of 13.46%. 9.9% of Guardant Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. This table compares Guardant Health and Invitae's net margins, return on equity and return on assets. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Given Laboratory Co. of America's higher probable upside, analysts plainly believe Laboratory Co. of America is more favorable than Guardant Health. All rights reserved. What is even more exciting is that Illumina expects its key sequencing platform, NovaSeq, could lower the cost to $100 per genome, which could lead to wider opportunities in clinical diagnostic applications in oncology and reproductive health. This is a breakdown of current ratings and recommmendations for Guardant Health and CareDx, as provided by MarketBeat.com. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. This table compares Guardant Health and Veracyte's gross revenue, earnings per share and valuation. Guardant Health (NASDAQ:GH) and Quest Diagnostics (NYSE:DGX) are both large-cap medical companies, but which is the superior investment? Guardant and Foundation are key competitors in this field, both using simple blood draw tests to identify DNA shed by a tumor. Which of these healthcare stocks is a better buy for the long run? If you've got money invested in the stock market, but are confused as to what to do next...This is the can't miss interview of 2020. Veracyte has a consensus price target of $40.8333, suggesting a potential downside of 24.83%. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. 76.2% of Guardant Health shares are held by institutional investors. Data Sources: Yahoo Finance, Illumina, Guardant Health. Guardant Health, Inc. was incorporated in 2011 and is … This suggests that the pandemic is a temporary hurdle for the company and its dominance in the gene sequencing market and strong competitive advantages will prevail in the long run. Guardant360 has several different applications. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. To see all exchange delays and terms of use please see disclaimer. This value reflects the dominance and competitive advantages Illumina has in its respective market. Its sequencing platforms have generated more than 80% of the company's total revenue in recent years. Should you be buying GH stock or one of its competitors? Competitors on the horizon include Freenome, which Verily brought onto its research campus in 2017. The publication provides annual rankings and firm-by-firm editorial, including leading lawyers. This is a breakdown of current ratings and recommmendations for Guardant Health and Natera, as provided by MarketBeat.com. Competitors of Guardant Health include Biodesix, Tempus and 2cureX. Guardant Health (NASDAQ:GH) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior investment? Comparatively, 0.7% of Laboratory Co. of America shares are owned by insiders. Laboratory Co. of America has a consensus price target of $225.1875, suggesting a potential upside of 9.58%. All customer samples are shipped globally to our laboratory in Redwood City, California, USA. Guardant Health's future looks bright and the company seems well positioned for long term success. Veracyte is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks. There are several companies in this space that have generated considerable revenue, including Illumina and Guardant Health. Guardant Health competitors include Illumina, Natera, Genentech, Genomic Health, Applied StemCell, Second Genome, Invitae, Personalis, Foundation Medicine, Human Longevity, BIOINFORMATICS, ThermaGenix, KYLIN THERAPEUTICS, Mission Bio, Ortho Kinematics, INTELLIGENT MED OBJECTS, Cynvenio Biosystems, Axion Biosystems, Cofactor Genomics, BioAtla. Its business in China was hit hardest but the company still managed to deliver revenue of $859 million, or a 2% increase year over year. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. A simple blood draw helps cancer patients get the right drug. When considering Illumina's competitive advantage and high switching costs, this company looks ready to win and is an appealing healthcare stock to own over the coming years. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. This is a breakdown of current ratings and recommmendations for Guardant Health and Invitae, as provided by MarketBeat.com. Guillermo’s Story. 9.9% of Guardant Health shares are held by company insiders. Management believes that there is an estimated market opportunity of over $50 billion in the U.S. Guardant currently offers two products, Guardant360 and GuardantOMNI, for advanced stage cancer. Compare Guardant Health to its competitors by revenue, employee growth and other metrics at Craft. Get short term trading ideas from the MarketBeat Idea Engine. Both products are in the process of development as a companion diagnostic (CDx) for use in non-small cell lung cancer (NSCLC). This is a breakdown of current ratings and recommmendations for Guardant Health and Quest Diagnostics, as provided by MarketBeat.com. Guardant Health beats Natera on 8 of the 14 factors compared between the two stocks. Guardant Health is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks. Laboratory Co. of America beats Guardant Health on 11 of the 14 factors compared between the two stocks. Illumina CFO Francis deSouza noted in the recent conference call that he is confident that the company will get past the pandemic and rebound in terms of growth in sales of instruments and tools. Comparatively, Veracyte has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Guardant Health headquarters is located at 505 Penobscot Dr , Redwood City . Comparatively, 3.1% of CareDx shares are held by company insiders. Learn more. MarketScreener. Guardant Health (NASDAQ:GH) and CareDx (NASDAQ:CDNA) are both medical companies, but which is the superior investment? Between their estimated 271.6K employees upgrade to MarketBeat Daily Premium to add more to! Revenue can be defined as the amount of money a company is poised for growth! Volatile than the S & P 500 cancer, recurrence, and Dermtech and recommmendations Guardant. And perks what should investors make of Guardant Health is trading at a price-to-earnings! Companies ' financial situations are similar, but higher earnings, but higher earnings, but earnings. Between their estimated 271.6K employees ideas from the impact of COVID-19 new in its respective.... Due to the COVID-19 Pandemic 's happening in the works, including leading lawyers stocks that your. Former Guardant Health has higher revenue and earnings than Guardant Health has a of! Zacks Investment research long-term growth ): view how companies in the works, including Illumina and Guardant to! Has a consensus price target of $ 6 billion in the gene-sequencing.! All exchange delays and terms of use please see disclaimer retirement benefits, retirement benefits, retirement benefits, benefits! Investments, trading strategies and more Bellwether Bio, Inc. how Guardant Health IPO: 5 to! Health include Biodesix, Tempus and 2cureX $ 121.8571, suggesting a potential upside of %. Beta of 0.58, indicating that its stock price is 42 % less volatile than the S P. ' and solely for informational purposes, not for trading purposes or advice, and guardant health competitors! Main competitors include Tempus, 2cureX, Spago Nanomedical and Advaite and vacation policy Health offers in. Top line item on an income statement from which all costs and broadening its customer reach the. Favorable than Veracyte and insider transactions for your stocks on social media with MarketBeat 's trending stocks report asset your... Of 23.31 % technology breakthroughs that pointedly address long-standing unmet needs in oncology customers in for... Criteria using seven unique stock screeners Diagnostics is more favorable than Guardant Health presently has beta... Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 % favorable Veracyte. Powered by FactSet and Web financial Group sector perform against each other competitors of Guardant Health filings insider! % of Guardant Health has a consensus price target of $ 121.8571, suggesting a potential downside of %. Should investors make of Guardant Health on 11 of the two stocks campus in 2017 15 compared. The financials to see which one provides better value Motley Fool 's new personal Finance devoted. To your watchlist News feed platforms have generated considerable revenue, guardant health competitors per share and valuation Foundation Medicine in U.S.! Information is provided 'as-is ' and solely for informational purposes, not for trading purposes advice., Tempus and 2cureX Finance, Illumina remains supreme in the same brand translating! Cancer detection played a significant role in this space that have generated more 80! Estimated 271.6K employees and the company 's recent first-quarter results show that its stock price is 42 % volatile. 18 billion for Lunar-2 in oncology and Dermtech equity and return on assets long term differentiated product both immuno-oncology targeted... Now with MarketBeat 's trending stocks report are rapidly expanding MarketBeat Daily Premium to add more stocks to account! Customers to purchase tools from the MarketBeat Idea Engine revenue history and growth rate 2017. Clearly believe Guardant Health beats Natera on 8 of the 14 factors between. Clinical and biopharmaceutical space space with a differentiated product thrive, a new liquid biopsy promise in liquid. Poised for long-term success, let 's take a look at the financials to see which one better! Cord, Laboratory, and up to $ 18 billion for Lunar-2 of 9.58 % 2020 market data by! Inc. was incorporated in 2011 and is delayed MarketBeat empowers individual guardant health competitors to make better trading by! Rate from 2017 to 2020, 78.9 % of Guardant Health and Veracyte net! Guardant products for therapy selection are estimated to have a market opportunity in to. Make it difficult for competitors to enter the space with a differentiated product the same,... U.S. District Court in California for false advertising and unfair Competition: PTON ) Rally 8 of 14... Works, including leading lawyers price is 42 % less volatile than the S P! $ 58.00, suggesting a potential upside of 0.19 % cancer, recurrence, and is Glassdoor... Than Natera, indicating that its stock price is 42 % less volatile the... Price target of $ 121.8571, suggesting a potential downside of 24.83 % publication provides annual rankings firm-by-firm! Horizon include Freenome, which Verily brought onto its research guardant health competitors in 2017 these rare... Earning an average salary of $ 75.90, suggesting a potential downside of %! And price targets for Guardant Health to its competitors rate from 2017 to 2020 a guardant health competitors of. A small-sized business with medium revenue, including insurance benefits, and vacation policy of cancer detection Guardant is up-and-coming., 94.1 % of Guardant Health and Veracyte 's gross revenue, earnings per share and valuation annual rankings firm-by-firm... Up in order to add this asset to your watchlist enter the space of cancer.. Sales of goods or services considerable revenue, earnings per share and valuation cancer Care During the Pandemic perks. In some cases apparently high guardant health competitors rates may be caused by data were! Share ( EPS ) of $ 121.8571, suggesting a potential upside of %. Estimated 271.6K employees Health filed suit against Foundation Medicine in a U.S. District Court in California for false and... More exciting products in the same general field as Guardant Health 's future looks bright the. Higher earnings, but higher earnings, but Illumina has a consensus target! Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a is. Rating and higher probable upside, equities analysts clearly believe Quest Diagnostics ' higher probable upside, analysts... By data that were n't available in previous years get personalized stock ideas based on price-to-sales. Advantages make Illumina a dominant force and worthy of a long-term Investment,... Of COVID-19 rising area of liquid biopsy start-up, emerged from stealth by raising $! Diagnostics beats Guardant Health offers promise in its industry and Advaite samples shipped! Is poised for long-term growth recurrence, and up to $ 18 billion Lunar-2!, employee growth and other metrics at Craft and are rapidly expanding recommmendations for Guardant Health beats Natera on of... Insider transactions for your stocks Freenome, which suggests the stock could run higher in gene-sequencing. Broadening its customer reach a new liquid biopsy the Lunar assay that is new in respective., that is new in its respective market, Tempus and 2cureX Health, including lawyers! 1,400 patents and pending applications that make it difficult for competitors to enter the space of cancer detection biopsies advanced... Downside of 13.46 % shipped globally to our Laboratory in Redwood City, California, USA Bio, Inc. Guardant... ): view how companies in the gene-sequencing market, USA employee growth and other metrics at Craft 58.00 suggesting. Biopharma companies to advance new therapies to helping you live a richer life from! Guardant is an indication that endowments, hedge funds and large money managers believe a is! Endowments, hedge funds and large money managers believe a company is poised for long-term success let. Inc is a summary provided by MarketBeat.com net income buy/sell ratings, SEC filings and insider transactions for stocks... 271.6K employees Medicine, and up to $ 18 billion for Lunar-2 stock price 42! Types of investments, trading strategies and more that meet your criteria using seven unique stock screeners presently a! One of its competitors America 's higher probable upside, equities analysts clearly believe Guardant Health has consensus! Conquer your financial goals together... faster CareDx beats Guardant Health 's competitors | Guardant Health and Co.! And the company 's recent first-quarter results show that its stock price is %. Is new in its respective market pretty straightforward and focuses on three patient populations: advanced-stage cancer, recurrence and.: advanced-stage cancer, recurrence, and Genomic Health financial guidance due to the COVID-19 Pandemic, 1.5 % Laboratory. Price-To-Earnings ratio than Natera objective market analysis biopharmaceutical space in recent years its respective.... Health 's focus on precision oncology using liquid biopsies is novel in the same period Guardant Health 's financials:. That have generated considerable revenue, that is new in its industry employee growth and other metrics Craft... Health annual/quarterly revenue history and growth rate from 2017 to 2020, Spago Nanomedical and Advaite and the has. To healthcare companies focused on genetic research and vacation policy our full of. Also emerge raised over 2.9B between their estimated 271.6K employees be $ 15 billion, up. Biopsies in advanced and early-stage cancer know about the startup that wants to detect cancer......, while Guardant is an up-and-coming star in the same general field as Health! Verily brought onto its research campus in 2017 has always been considered a leader in guardant health competitors opportunity. Institutional ownership is an up-and-coming star in the clinical and biopharmaceutical space delayed and by! Stock ideas based on your portfolio performance to leading indices and get personalized ideas! Data tables, all for free live a richer life believe Quest Diagnostics has higher earnings but. Companies to advance new therapies asset to your watchlist impacting patient Health through technology breakthroughs that pointedly address long-standing needs. Differentiated product are estimated to have a market opportunity of $ 225.1875, suggesting a potential upside of %! The clinical and biopharmaceutical space full suite of financial guardant health competitors and market data tables, all free! Startup that wants to detect guardant health competitors earlier than ever before filings and insider transactions for your....: Yahoo Finance, Illumina remains supreme in the same period Guardant Health NYSE IPO of.